Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
10 evidence topics · 9 sources
Myasthenic crisis: frequency, triggers, and outcomes
“Myasthenic crisis (MC) is a life-threatening manifestation of myasthenia gravis (MG) defined by respiratory insufficiency that requires the use of invasive or non-invasive ventilation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MC occurs in approximately 15%-20% of patients with MG usually within the first 2 to 3 y of the disease course.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many crises have a specific trigger with respiratory infections being most common; however, no specific trigger is found in 30%-40% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MG patients with a history of MC, severe disease, oropharyngeal weakness, muscle-specific kinase (MuSK) antibodies and thymoma appear to be at higher risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate in United States cohorts is less than 5% and mortality in MC seems to be driven by age and other medical co-morbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A myasthenic crisis (MC) is a more severe, life-threatening escalation of muscle weakness that leads to respiratory failure, necessitating intensive care unit admission with assisted ventilation, usually requiring an inpatient stay period of several weeks, often in the range of 2–4 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20% of patients with gMG are estimated to experience MC during a period of 3 years or longer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Myasthenic crisis: Ontario, Canada, population-based incidence
Exacerbations and crises: predictors, United States generalized myasthenia gravis
“Among 6,195 patients with gMG (mean age: 61.1 years; female: 49.1%), higher event risk was associated with use of immunoglobulin [hazard ratio (HR) = 1.54], baseline dysarthria (HR = 1.45), general and other muscle-specific weaknesses (HR = 1.38), use of non-steroidal immunosuppressants (HR = 1.37), dysphagia (HR = 1.28), weight loss (HR=1.27), dyspnea (HR = 1.23), ptosis (HR = 1.20), absence of other autoimmune disorders (HR=1.18), and male sex (HR = 1.15; all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: persistent moderate or severe weakness
Glucocorticoid toxicity: United States commercially insured adults with generalized myasthenia gravis
“Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (≥5 mg/d: 1537 [40.9%]; ≥10 mg/d: 860 [22.9%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study period, incident GC toxicities were more common among patients in the any GC use cohort than the no GC use cohort (61.9% vs 52.3% with ≥1 toxicity), with a trend of increasing incidence with increasing GC use (≥5 mg/d: 62.9%; ≥10 mg/d: 67.3%; all P < .001” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, a greater proportion of patients with any GC use than no GC use had ≥3 incident GC toxicities (16.5% vs 9.5%), with this proportion rising with mean PEDD ≥5 mg (18.9%) and mean PEDD ≥10 mg (22.8%; all P <.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both acute and chronic incident GC toxicities were more common in the any GC use cohort than the no GC use cohort (acute: 28.5% vs 19.1%; chronic: 51.9% vs 43.8%; both P <.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid toxicity: recognized adverse effects and higher-risk patients
Refractory disease: share and crisis rates in U.S. administrative health plan data
“Rates of myasthenic crises, exacerbations, inpatient hospitalizations, and emergency room (ER) visits over a 1-year period were measured for 403 refractory, 3,811 nonrefractory, and 403 non-MG control patients from two administrative health plan databases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with nonrefractory patients, a significantly greater percentage of refractory patients had at least one myasthenic crisis (21.3% vs. 6.1%; P < 0.001) and at least one exacerbation (71.2% vs. 32.4%; P < 0.001) over a 1-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: share and characteristics in a U.S. tertiary neuromuscular clinic, 2003 to 2011
“A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease: share assumed in the ICER evaluation
Persistently uncontrolled disease over 8 years of follow-up: Spanish referral cohort
“The proportion adequately controlled (AC) patients increased from 62.0% at 2 years after first visit to 81.9% after 8 years of follow-up. 47.3% of patients remained AC in every observation, and 17.7% remained not adequately controlled (NC) in every observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AE-related drug interruption rates were higher in NC patients (ranging from 50% to 100% during the study).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote